STRYKER CORP
SYKNYSETrading Snapshot
- Day Range
- $275.63 β $280.15
- 52-Week Range
- $267.00 β $392.55
- Volume
- $7.77B
- Avg Volume
- $10.30B
- Shares Outstanding
- 383.4M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $25.12B
- Last Q Revenue
- $6.59B
- P/E Ratio
- 28.3
- P/S Ratio
- 4.1x
- EPS (TTM)
- $9.65
- Dividend Yield
- 1.25%
Why Investors Own SYK
- βHigh-growth profile β revenue up +43.0% YoY with expanding US Equity exposure.
- βHealthy economics β 38% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
STRYKER CORP
SYKAbout STRYKER CORP
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
STRYKER CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SYK price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
STRYKER CORP announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.